Issue № 31 | 2018 (1)
An approach is proposed to find reference values of incremental cost-effectiveness ratio (ICER) for the assessment of pharmacoeconomic effectiveness of drugs for lists of vital and essential drugs. The essence is to use a unified simple method of calculation of ICER for drugs within the therapeutic groups already included into the list. The criteria of effectiveness should be separately defined for each area. The method was developed on the example of antineoplastic drugs. The numerator in the formula of ICER is the difference in costs between compared drugs, and the denominator is the difference in saved life years or life years without tumor progression obtained from the overall survival rate or progression-free survival in randomized clinical trials (RCT). RCT that form the basis for ICER calculation should demonstrate statistically significant advantages of the proposed drug compared to the drug already included into the list. The calculation considers the cost of drugs only.
incremental cost-effectiveness ratio (ICER), list of vital and essential drugs, antineoplastic drugs.
Omelyanovsky V. V., Avxentyeva M. V., M. V. Sura M. V., Khachatryan G. R., Savilova A. G. Approaches to the Creation of a Unified Method of Calculation of Incremental Cost-Effectiveness Ratio for the Re-Consideration of Lists of Medical Drugs; an Example of Antineoplastic Drugs. Medical Technologies. Assessment and Choice. 2018; 1(31): 10–20.